Table 3.
Baseline Characteristicsa
| Variable | Dapsone (n=9) | Placebo (n=10) | P Value |
|---|---|---|---|
| Starting steroid dosage, mean, median (range), mg | 25.5, 20 (15-30) | 29, 35 (20-40) | .51 |
| Taper schedule (patients, No.) | |||
| Daily (8) | Daily (6) | .30 | |
| Every other day (1) | Every other day (4) | ||
| Immunosuppressive drugs | |||
| Azathioprine (3) | Azathioprine (7) | ||
| Mycophenolate mofetil (1) | Mycophenolate mofetil (1) | ||
| Gold (1) | |||
| Sex, No, (%) | |||
| Female | 4 (44) | 4 (40) | .61 |
| Male | 5 (56) | 6 (60) | |
| Duration of disease, mean, median (range), mo | 19.6, 22.5 (3-39) | 40.0, 25 (5-180) | .35 |
| Oral/skin | 2 Oral and skin | 3 Oral and skin | .52 |
| 3 Skin | 5 Oral | ||
| 4 Oral | 2 Skin |
a
An intention-to-treat analysis.